The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 02, 2022

Filed:

Aug. 31, 2017
Applicant:

Nanjing Legend Biotech Co., Ltd., Nanjing, CN;

Inventors:

Qiuchuan Zhuang, Nanjing, CN;

Xiaohu Fan, Edmonton, CA;

Lei Yang, Huainan, CN;

Pingyan Wang, Fengyang, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/54 (2006.01); C07K 14/705 (2006.01); A61K 35/17 (2015.01); C12N 15/62 (2006.01); A61P 35/02 (2006.01); C12N 5/10 (2006.01); A61P 35/00 (2006.01); C07K 19/00 (2006.01); C12N 15/867 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70517 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 19/00 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/86 (2013.01); C12N 15/867 (2013.01);
Abstract

The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.


Find Patent Forward Citations

Loading…